Global Peripheral Neuropathy Market, By Treatment (Pain Relievers, Anti-Seizure Medications, Antidepressants, Others), Therapy Type (Transcutaneous Electrical Nerve Stimulation (TENS), Physical Therapy, Immunoglobulins, Others), Route of Administration (Oral, Parenteral, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Industry Trends and Forecast to 2029
Market Analysis and Insights
Peripheral nervous system is known to connect the nerves from the spinal cord and brain, or central nervous system to the rest of your body. Peripheral neuropathy refers to the disorder caused due to the damage to the spinal cord (peripheral nerves) and nerves outside of the brain. The disorder causes numbness and pain, also weakness in your hands and feet.
- The disease often occurs due to variety of systemic diseases, medications, toxic exposures, hereditary disorders and infections. Global peripheral neuropathy market was valued at USD 262.69 million in 2021 and is expected to reach USD 373.61 million by 2029, registering a CAGR of 4.4% during the forecast period of 2022-2029.
Report Metric |
Details |
Forecast Period |
2022 to 2029 |
Base Year |
2021 |
Historic Years |
2020 (Customizable to 2019 - 2014) |
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
Segments Covered |
Treatment (Pain Relievers, Anti-Seizure Medications, Antidepressants, Others), Therapy Type (Transcutaneous Electrical Nerve Stimulation (TENS), Physical Therapy, Immunoglobulins, Others), Route of Administration (Oral, Parenteral, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
Countries Covered |
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa |
Market Players Covered |
Teikoku Pharma USA, Inc (US), Sun Pharmaceutical Industries Ltd (India), Galen Limited (US), Cipher Pharmaceuticals Inc (Canada), Mylan N.V. (US), Aurobindo Pharma (India), ZydusCadila (India), Hikma Pharmaceuticals PLC (UK), ACI Limited (Bangladesh), Apotex Inc (Canada), Johnson & Johnson Services, Inc (US), Pfizer Inc (US), Arbor Pharmaceuticals (US), ALMATICA PHARMA (India), Alkem Labs (India), Amneal Pharmaceuticals LLC (US), Novartis AG (Switzerland), and Lupin, among others |
Peripheral Neuropathy Market Dynamics
Drivers
-
Prevalence of Diabetes
The rise in the prevalence of diabetes across the globe acts as one of the major factor driving the growth of peripheral neuropathy market.
-
Increase In Mergers and Acquisitions
The increase in the number of mergers and acquisitions among manufacturers and research organizations to provide efficient medical care to patients and generate significant revenues by their sales options results in the expansion of the market.
-
Chemotherapy Treatments
The rise in the number of chemotherapy treatments accelerate the market growth. Medications and side-effects associated with various treatments could also lead to peripheral neuropathy.
-
Financial support to the researchers for developing novel intervention
Various public and private organizations are increasing their investments in developing novel interventions and treatments further influence the market.
Additionally, surge in healthcare expenditure, increase in demand for effective therapies, and development in technology positively affect the peripheral neuropathy market.
Opportunities
Furthermore, development of novel treatment extends profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, rise in awareness about peripheral neuropathy will escalate the growth of peripheral neuropathy market growth.
Restraints/Challenges
On the other hand, adverse effects associated with drugs and stringent regulatory policies are expected to obstruct the market growth. The generic competitions of drugs are projected to challenge the peripheral neuropathy market in the forecast period of 2022-2029.
This peripheral neuropathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on peripheral neuropathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The peripheral neuropathy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Peripheral Neuropathy Market
The COVID-19 negatively impacted the peripheral neuropathy market. The outbreak of the pandemic caused disruption in the supply chains of the drugs that lead to supply gaps for countries dependent on trade affairs for drugs. However, the supply chain disruptions and logistics are being eased in the post-second wave.
Global Peripheral Neuropathy Market
The peripheral neuropathy market is segmented on the basis of treatment, therapy type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Pain Relievers
- Anti-Seizure Medications
- Antidepressants
- Others
On the basis of treatment, the peripheral neuropathy market is segmented into pain relievers, anti-seizure medications, antidepressants and others.
Therapy Type
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Physical Therapy
- Immunoglobulins
- Others
The therapy type segment for peripheral neuropathy market includes transcutaneous electrical nerve stimulation (TENS), physical therapy, immunoglobulins and others.
Route of Administration
- Oral
- Parenteral
- Others
Route of administration segment of peripheral neuropathy market is segmented into oral, parenteral and others.
End-Users
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
On the basis of end-users, the peripheral neuropathy market is segmented into hospitals, homecare, specialty clinics and others.
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
On the basis of distribution channel, the peripheral neuropathy market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.
Pipeline Analysis
Off-label prescription of several is widespread, with a limited number of prescription drugs available for neuropathic pain. Teikoku Pharma USA, Inc, Sun Pharmaceutical Industries Ltd, Galen Limited, and Cipher Pharmaceuticals Inc, among others are some of the manufacturers involved with the development of peripheral neuropathy.
Peripheral Neuropathy Market Regional Analysis/Insights
The peripheral neuropathy market is analysed and market size insights and trends are provided by country, treatment, therapy type, route of administration, end-users and distribution channel as referenced above.
The countries covered in the peripheral neuropathy market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the peripheral neuropathy market due to the increasing prevalence of diabetes and cancer within the region.
Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the growing number of geriatric populations in the region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Peripheral Neuropathy Market Share Analysis
The peripheral neuropathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to peripheral neuropathy market.
Some of the major players operating in the peripheral neuropathy market are Teikoku Pharma USA, Inc (US), Sun Pharmaceutical Industries Ltd (India), Galen Limited (US), Cipher Pharmaceuticals Inc (Canada), Mylan N.V. (US), Aurobindo Pharma (India), ZydusCadila (India), Hikma Pharmaceuticals PLC (UK), ACI Limited (Bangladesh), Apotex Inc (Canada), Johnson & Johnson Services, Inc (US), Pfizer Inc (US), Arbor Pharmaceuticals (US), ALMATICA PHARMA (India), Alkem Labs (India), Amneal Pharmaceuticals LLC (US), Novartis AG (Switzerland), and Lupin , among others.
SKU-